Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann S LaCasce

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
Hematological Oncology|June 13, 2019
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory diseaseAnn S LaCasce
The Oncologist|June 24, 2006
Post-transplant lymphoproliferative disordersAnn S LaCasce
Current Opinion in Hematology|April 17, 2012
Biology of double-hit B-cell lymphomasR Coleman Lindsley, Ann S LaCasce
Expert Opinion on Investigational Drugs|May 22, 2008
EnzastaurinYi-Bin Chen, Ann S LaCasce
Oncology (Williston Park, N.Y.)|December 9, 2010
Lymphoma: risk and response after solid organ transplantCaron A Jacobson, Ann S LaCasce
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?Nmazuo W Ozuah, Ann S LaCasce
Seminars in Hematology|April 3, 2008
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce, Arnold S Freedman
British Journal of Haematology|November 22, 2018
Current considerations in AYA Hodgkin lymphomaJennifer L Crombie, Ann S LaCasce
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Primary mediastinal large B-cell lymphomaJason E Faris, Ann S LaCasce
Frontiers in Oncology|March 23, 2019
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative DisordersJennifer L Crombie, Ann S LaCasce
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
Hematological Oncology|June 13, 2019
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory diseaseAnn S LaCasce
The Oncologist|June 24, 2006
Post-transplant lymphoproliferative disordersAnn S LaCasce
Current Opinion in Hematology|April 17, 2012
Biology of double-hit B-cell lymphomasR Coleman Lindsley, Ann S LaCasce
Expert Opinion on Investigational Drugs|May 22, 2008
EnzastaurinYi-Bin Chen, Ann S LaCasce
Oncology (Williston Park, N.Y.)|December 9, 2010
Lymphoma: risk and response after solid organ transplantCaron A Jacobson, Ann S LaCasce
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?Nmazuo W Ozuah, Ann S LaCasce
Seminars in Hematology|April 3, 2008
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphomaAnn S LaCasce, Arnold S Freedman
British Journal of Haematology|November 22, 2018
Current considerations in AYA Hodgkin lymphomaJennifer L Crombie, Ann S LaCasce
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Primary mediastinal large B-cell lymphomaJason E Faris, Ann S LaCasce
Frontiers in Oncology|March 23, 2019
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative DisordersJennifer L Crombie, Ann S LaCasce
Pageof 13